Daxor Corporation Showcases Innovative Blood Volume Analysis At Acc’s 74th Annual Scientific Session

$DXR

Daxor Corporation (Nasdaq: DXR), a leading company in blood volume measurement, recently presented its latest advancements at the American College of Cardiology’s (ACC) 74th Annual Scientific Session in Chicago. This event is a major gathering for cardiology professionals worldwide.

At the conference, new research from Duke University Medical Center highlighted that Blood Volume Analysis (BVA) is more effective than traditional pressure-based methods in managing heart failure. Dr. Marat Fudim from Duke University led a session titled “When Pressure ≠ Volume: Understanding Complex Hemodynamic Situations and Pitfalls,” which drew an audience of over 400 attendees. He explained that relying on pressure readings alone can misrepresent a patient’s true blood volume, leading to less effective treatments.

Additional research from Duke University, “Correlation Between Changes in Total Blood Volume and Measures of Congestion During Heart Failure Hospitalization,” revealed that commonly used methods like urine output, weight changes, and biomarkers such as CA-125 and NT–proBNP do not reliably reflect a patient’s actual blood volume. This challenges the traditional approach to heart failure management and supports using BVA for more precise and effective treatment.

John L. Jefferies, MD, MBA, MPH, Chief Medical Officer at Daxor, emphasized that these findings add to the growing evidence that BVA provides clear, accurate insights for doctors, helping them make better treatment decisions and improve patient outcomes. Daxor’s BVA-100® (Blood Volume Analyzer) remains the only FDA-cleared diagnostic test that accurately measures blood volume. It has been used in over 65,000 tests at top U.S. hospitals, helping reduce hospital readmissions and deaths in heart failure and critical care patients.

Daxor is also conducting ongoing clinical trials in heart failure treatment, supported by the National Institutes of Health (NIH) and contracts with the U.S. Department of Defense to develop blood volume analyzers for battlefield medicine- By continuing to innovate, Daxor aims to improve patient care and outcomes worldwide.

DISCLAIMER: This content is for informational purposes only and is not intended as investment advice. Investing carries risks, including potential loss of capital. Please conduct your own research and consult a financial advisor before making any investment decisions.